Beactica Initiates Drug Discovery Collaboration with Medivir

11-Jun-2014 - Sweden

Beactica, announced that it has entered into an agreement with Medivir AB. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement were not disclosed.

“We are pleased that Medivir has selected Beactica to advance one of their prioritized discovery programmes”, said Beactica CEO, Dr Per Källblad. “Medivir is at a very exciting point in their development and we are looking forward to tackle this challenging project together with their team of innovative scientists”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances